Shares of Mirna Therapeutics, Inc. (NASDAQ:MIRN) have been given an average recommendation of “Hold” by the six ratings firms that are covering the stock, MarketBeat reports. Six equities research analysts have rated the stock with a hold rating. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $1.83.

Separately, Cantor Fitzgerald restated a “hold” rating and set a $2.00 target price on shares of Mirna Therapeutics in a report on Thursday, April 13th.

An institutional investor recently raised its position in Mirna Therapeutics stock. Vanguard Group Inc. raised its position in shares of Mirna Therapeutics, Inc. (NASDAQ:MIRN) by 15.2% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 178,387 shares of the biotechnology company’s stock after buying an additional 23,520 shares during the period. Vanguard Group Inc. owned 0.86% of Mirna Therapeutics worth $391,000 as of its most recent SEC filing. Institutional investors and hedge funds own 37.34% of the company’s stock.

Mirna Therapeutics (NASDAQ MIRN) traded down 0.6733% during midday trading on Tuesday, hitting $1.4899. 52,410 shares of the stock were exchanged. The firm’s market capitalization is $31.07 million. Mirna Therapeutics has a one year low of $1.12 and a one year high of $4.74. The company has a 50 day moving average price of $1.67 and a 200 day moving average price of $1.94.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally reported by Financial Market News and is the sole property of of Financial Market News. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of United States & international copyright legislation. The legal version of this piece of content can be read at

Mirna Therapeutics Company Profile

Mirna Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a pipeline of micro ribonucleic acid (RNA)-based oncology therapeutics. The Company is developing mimics of naturally occurring microRNAs that are designed to restore the tumor suppressor activity and aid appropriate anti-tumor immune response.

Receive News & Ratings for Mirna Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirna Therapeutics Inc. and related companies with's FREE daily email newsletter.